ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Wednesday, 18 November 2026 NSE & BSE filings, as they land
ALFA News Straight from the exchange filing
Regulatory Approval

Infinium Pharmachem Gets In-Principle NSE Approval for Main Board Migration

Infinium Pharmachem Limited has secured in-principle approval from the National Stock Exchange of India to migrate its equity shares from the SME Emerge platform to the Main Board. This regulatory milestone follows shareholder approval in September 2026 and marks a transition toward enhanced market visibility.

Multiracial crop anonymous people demonstrating flask and glass stick with chemical thick substance in laboratory in soft focus. Stock photo illustrating Infinium Pharmachem's regulatory approval story.
Photo: Ravi Kant / Pexels
Key numbers
Market Cap ₹429.87 CrSmall Cap
P/E Ratio 35.38Sector 48.58
Promoter Holding 64.91%No Pledges
1Yr Price Change 28.33%Annual Growth

Key highlights

  • In-principle approval granted for migration of 15,583,120 equity shares
  • Approval pertains to shares with a face value of Rs 10 each
  • Regulatory authorization remains valid for a period of 45 days
  • Company must submit final listing application and agreement for trading commencement
  • Migration follows a 49.17 percent annual growth in net profit for the previous fiscal year

Transition from SME Emerge to NSE Main Board

Infinium Pharmachem is moving from the NSE SME Platform (EMERGE) to the Main Board, a step that typically improves liquidity and broadens the investor base. The company reported annual operating revenue of ₹189.63 crore and a net profit of ₹12.15 crore for the last financial year. This migration path was formalised following shareholder approval via postal ballot on September 28, 2026.

The exchange's in-principle approval, valid for 45 days, requires the company to complete the formal listing application process before final trading permissions are granted on the Main Board.

Steps Toward Final Trading Approval

  • Submission of the formal listing application to the National Stock Exchange
  • Execution of the equity listing agreement as per exchange requirements
  • Verification of compliance documents within the 45-day validity window
  • Issuance of the final listing and trading notice by the exchange
  • Migration of 1.55 crore equity shares to the Main Board trading system
Infinium Pharmachem · share price, past month

Strategic Expansion and Sector Outlook

The pharmaceutical manufacturer has recently scaled its operations, including the commissioning of a contrast media raw materials facility at GIDC Sojitra on January 16, 2026. Management has previously shared a target of achieving ₹100 crore in annual revenue from the contrast media vertical over the next three years, with anticipated EBITDA margins of approximately 30 percent. Furthermore, the company is working toward a long-term goal of capturing a 25 percent market share in the Indian iodine market by 2030, supported by international distribution agreements like the five-year deal signed with Japan-based K Sakai & Company in June 2025.

Earlier announcements by Infinium Pharmachem
DateAnnouncementAmount
06 Nov 2026Board approval of unaudited financial results for the half year ended 30 September 2026Source: NSE filing–
30 Sep 2026Submission of Annual Secretarial Compliance Report for migration from NSE Emerge to NSE Main BoardSource: NSE filing–
28 Sep 2026Approval by shareholders via Postal Ballot for migration of equity shares to the Main Board of NSESource: stocksigma.ai–
20 May 2026Resumption of manufacturing operations at GIDC Sojitra plant following GPCB revocation orderSource: millionshq.com–
16 Jan 2026Commissioning of contrast media raw materials manufacturing facility at GIDC SojitraSource: NSE filing–
26 Jun 2025Execution of 5-year exclusive distribution agreement with Japan-based K Sakai & CompanySource: NSE filing–

What to watch next

  • Submission of the final listing application to NSE within the 45-day approval window
  • Expansion of contrast media raw material production at GIDC Sojitra facility
  • Progress toward the target of 25 percent Indian iodine market share by 2030
Infinium Pharmachem · financial snapshot
Share price₹308.9
Market capitalisation₹429.87 Cr
Revenue (annual)₹189.63 Cr
Net profit (annual)₹12.15 Cr
P/E (TTM)35.38×Sector 48.58×
Promoter holding64.91%
FII holding0%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

Exchange filing by Infinium Pharmachem Limited announcing receipt of in-principle approval for migration to the NSE Main Board. Market figures from a third-party data provider.

Read the filing ↗
Every Infinium Pharmachem announcement on ALFA FilingsSee filings →

More in Approvals

All →